Marre M, Chatellier G, Leblanc H, Guyene T T, Menard J, Passa P
Service de Diabétologie, Hôpital Saint-Louis, Paris, France.
BMJ. 1988 Oct 29;297(6656):1092-5. doi: 10.1136/bmj.297.6656.1092.
To assess the effectiveness of inhibition of angiotensin converting enzyme in preventing diabetic nephropathy.
Randomised follow up study of normotensive diabetics with persistent microalbuminuria (30-300 mg/24 hours) treated with enalapril or its matched placebo for one year. Double blind for first six months, single blind for last six months.
Diabetic clinic in tertiary referral centre.
Treatment group and placebo group each comprised 10 normotensive diabetics with persistent microalbuminuria.
Treatment group was given enalapril 20 mg daily and controls matched placebo. Patients were given antihypertensive treatment after one year.
Albumin excretion, arterial pressure, and renal function.
In last three months of trial three of 10 patients taking placebo had diabetic nephropathy (albumin excretion greater than 300 mg/24 hours). No patients taking enalapril developed nephropathy and five showed normal albumin excretion (less than 30 mg/24 hours) (p = 0.005, Mann-Whitney test). Mean arterial pressure was reduced by enalapril throughout study (p less than 0.005) but increased linearly with placebo (p less than 0.05). Albumin excretion decreased linearly with enalapril but not placebo. An increase in albumin excretion with placebo was positively related to the increase in mean arterial pressure (r = 0.709, p less than 0.05, Spearman's rank test). With enalapril total renal resistances and fractional albumin clearances improved progressively (time effect, p = 0.0001).
Inhibition of angiotensin converting enzyme prevents development of nephropathy in normotensive diabetics with persistent microalbuminuria. This may be due to reduction in intraglomerular pressure and to prevention of increased systemic blood pressure. Future studies should compare long term effects of inhibitors of converting enzyme with other antihypertensive drugs.
评估抑制血管紧张素转换酶在预防糖尿病肾病方面的有效性。
对血压正常、持续性微量白蛋白尿(30 - 300毫克/24小时)的糖尿病患者进行随机随访研究,用依那普利或其匹配的安慰剂治疗一年。前六个月为双盲,后六个月为单盲。
三级转诊中心的糖尿病诊所。
治疗组和安慰剂组各由10名血压正常、持续性微量白蛋白尿的糖尿病患者组成。
治疗组每日服用依那普利20毫克,对照组服用匹配的安慰剂。一年后患者接受抗高血压治疗。
白蛋白排泄量、动脉压和肾功能。
在试验的最后三个月,10名服用安慰剂的患者中有3名出现糖尿病肾病(白蛋白排泄量大于300毫克/24小时)。服用依那普利的患者中无一人发生肾病,5人白蛋白排泄正常(小于30毫克/24小时)(曼-惠特尼检验,p = 0.005)。在整个研究过程中,依那普利使平均动脉压降低(p < 0.005),而安慰剂使其呈线性升高(p < 0.05)。依那普利使白蛋白排泄量呈线性下降,而安慰剂则不然。安慰剂组白蛋白排泄量的增加与平均动脉压的升高呈正相关(斯皮尔曼等级检验,r = 0.709,p < 0.05)。使用依那普利后,总肾阻力和白蛋白清除分数逐渐改善(时间效应,p = 0.0001)。
抑制血管紧张素转换酶可预防血压正常、持续性微量白蛋白尿的糖尿病患者发生肾病。这可能是由于肾小球内压降低以及全身血压升高得到预防。未来的研究应比较转换酶抑制剂与其他抗高血压药物的长期效果。